Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986202 | 0.86 | CHRNA7 (0.33) | CHRNA7NSD2CASP6HTR1ADRD2 | |
| SCHEMBL6985561 | 0.86 | HTR1A (0.34) | CHRNA7NSD2CASP6HTR1ADRD2 | |
| SCHEMBL6985396 | 0.82 | HTR1A (0.43) | HTR1ADRD2DRD4KCNH2 | |
| SCHEMBL25391347 | 0.77 | GABRA1 (0.32) | — | |
| SCHEMBL23006094 | 0.76 | HTR1A (0.44) | CHRNA7HTR1ADRD2DRD4KCNH2 | |
| SCHEMBL2609309 | 0.76 | CHRNA7 (0.46) | CHRNA7HTR1ADRD2DRD4KCNH2 | |
| SCHEMBL1854614 | 0.76 | CCR1 (0.46) | NSD2CASP6HTR1ADRD2DRD4 | |
| SCHEMBL30303121 | 0.76 | NSD2 (0.31) | NSD2CASP6 | |
| SCHEMBL1633704 | 0.76 | NSD2 (0.31) | NSD2CASP6 | |
| SCHEMBL7029297 | 0.74 | NSD2 (0.33) | NSD2CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | UNIV RUTGERS (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4452488-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | Rutgers, The State University Of New Jersey (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122078-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | NDC1, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRNA7 569/4885NSD2 748/4885CASP6 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.